EQ 6
Alternative Names: EQ-6; Ethoxyquin derivative - Axoprotego TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Johns Hopkins University
- Developer AxoProtego Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action HSP90 heat-shock protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peripheral nervous system diseases
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in USA (IV)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in USA (PO)
- 03 Aug 2020 AxoProtego Therapeutics plans a phase I/II study in Chemotherapy induced peripheral neuropathy